What We’ve Learned About GLP-1 Agonists to Date

Some of these drugs reduce the risk of heart attack and stroke in people with diabetes and in obese individuals without diabetes.

By
estaff
-
Published:
0
© Douglas Cliff | Getty Images The need for weekly injections has not affected interest in these drugs, which enable obese individuals to lose unprecendented amounts of weight safely. However, the drugs are costly and must be taken for life.

Glucagon-like peptide-1 (GLP‑1) receptor agonists are a class of medication used to lower blood glucose (sugar) levels in individuals with type 2 diabetes. The first GLP-1, exenatide (Byetta), was approved in 2005. Multiple GLP-1 products and formulations are now available.

To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access

RELATED ARTICLESMORE FROM AUTHOR